Top Markets
#1 GEKKO GEKKO +52.86%
#2 Helium Helium +45.40%
#3 Pons Pons +21.76%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +16.03%
#6 Collect on Fanable Collect on Fanable +14.73%
#7 Cysic Cysic +13.73%
#8 Ontology Gas Ontology Gas +13.53%
#9 o1.exchange o1.exchange +13.31%
#10 OpenGradient OpenGradient +11.75%
Coin of the day
GEKKO GEKKO
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Kedudukan dalam Saham #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Harga Saham
$9.60
Disegerakkan terakhir: 2025-05-21
Modal Pasaran
$1.08B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan OptiNose, Inc. (OPTN)

Kategori

Healthcare
Hasil untuk OptiNose, Inc. (OPTN)
Hasil pada Mar 2025 TTM: $81.86M
Menurut laporan kewangan terkini daripada OptiNose, Inc., hasil semasa syarikat (TTM) ialah $81.86M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $70.99M penurunan berbanding hasil pada tahun 2022 iaitu $76.28M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi OptiNose, Inc. dari 2015 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $81.86M 4.64%
2024 $78.23M 10.20%
2023 $70.99M -6.93%
2022 $76.28M 2.18%
2021 $74.65M 51.99%
2020 $49.12M 41.83%
2019 $34.63M 390.18%
2018 $7.07M 0.00%
2017 0.00 -100.00%
2016 $47.50M 55,782.35%
2015 $85.00K 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B 7,977.17%
IN